Multiplex Assay Kit for Advanced Glycation End Product (AGE) ,etc. by FLIA (Flow Luminescence Immunoassay) 
AGEs; Advanced Glycation End Products
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 444.00 US$ 461.00 US$ 486.00 US$ 520.00 US$ 554.00 US$ 606.00 US$ 682.00 US$ 853.00
- Quantity
Overview
Properties
- Product No.LMB353Ge
- Organism SpeciesPan-species (General) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathwayEndocrinologyCardiovascular biologyHormone metabolism
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Advanced Glycation End Product (AGE) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Advanced Glycation End Product (AGE) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 92-105 | 99 |
| EDTA plasma(n=5) | 85-96 | 93 |
| heparin plasma(n=5) | 94-103 | 98 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Advanced Glycation End Product (AGE) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Advanced Glycation End Product (AGE) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Advanced Glycation End Product (AGE) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 91-98% | 92-105% | 96-103% | 88-99% |
| EDTA plasma(n=5) | 94-101% | 96-104% | 90-101% | 90-97% |
| heparin plasma(n=5) | 90-103% | 78-91% | 82-96% | 85-98% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:AGE) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 50μL standard or sample to each well,
add 10μL magnetic beads,and 50μL Detection Reagent A,incubate 60min at 37°C on shaker;
3. Wash plate on magnetic frame for three times;
4. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
5. Wash plate on magnetic frame for three times;
6. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards,Labeled antigen and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest.A competitive inhibition reaction is launched between biotin labeled analytes of interest and unlabeled analytes of interest (Standards or samples) with the pre-coated antibody specific to analytes of interest. Following a wash to remove any unbound substances, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE) is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer. The MFI developed is reverse proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Threshold serum concentrations of tumour necrosis factor alpha (TNFα) as a potential marker of the presence of microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM)PubMed: S0198885912005642
- A long-standing hyperglycaemic condition impairs skin barrier by accelerating skin ageing processPubMed: 22017743
- Daily intake of vitamin D- or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D.Pubmed: 23829785
- Association of RAGE gene polymorphism with circulating AGEs level and paraoxonase activity in relation to macro-vascular complications in Indian type 2 diabetes mellitus patients.Pubmed: 23721855
- Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus.Pubmed:24397392
- Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complicationsPubmed:24984291
- Nitroxides prevent protein glycoxidation in vitro.Pubmed:25363554
- Serum advanced glycation end products are associated with insulin resistance in male nondiabetic patients with obstructive sleep apneaPubmed:25566941
- Ascorbic acid and protein glycationPubMed: 26163454
- Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazonePubMed: 26321377
- Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apneaPubMed: 25994997
- Glycation of bovine serum albumin by ascorbatePubMed: 26202868
- Impact of morbid obesity and bariatric surgery on antioxidant/oxidant balance of the unstimulated and stimulated human salivaPubMed: 26608886
- Inhibition of Advanced Glycation Endproduct Formation by Lotus Seedpod Oligomeric Procyanidins through RAGE-MAPK Signaling and NF-κB Activation in High-Fat-Diet Rats.PubMed: 26207852
- ADVANCED GLYCATION END PRODUCTS'RESPONSE TO RESISTANCE TRAINING IN POSTMENOPAUSAL WOMEN WITH TYPE II DIABETES140251:
- Effects of edible bird's nest on hippocampal and cortical neurodegeneration in ovariectomized ratsPubMed: 25920003
- Beneficial effects of urine-derived stem cells on fibrosis and apoptosis of myocardial, glomerular and bladder cellsPubmed:26952874
- Effects of S-Nitroso-N-Acetyl-Penicillamine (SNAP) on Inflammation, Lung Tissue Apoptosis and iNOS Activity in a Rabbit Model of Acute Lung InjuryPubmed:27334732
- The Receptor for Advanced Glycation End Products (Rage) and Its Ligands in Plasma and InfrainCavia (Guinea pig )inal Bypass VeinPubmed:26905625
- Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy.pubmed:28087385
- Inhibition of Methylglyoxal-Induced AGEs/RAGE Expression Contributes to Dermal Protection by N-Acetyl-L-Cysteine.pubmed:28214842
- Glutathione is the main endogenous inhibitor of protein glycation.pubmed:28218612
- Establishment of a rabbit model to study the influence of advanced glycation end productsaccumulation on osteoarthritis and the protective effect of pioglitazone.pubmed:26321377
- Advanced glycation end products promote VEGF expression and thus choroidal neovascularization via Cyr61-PI3K/AKT signaling pathwaypubmed:29097668
- Lychee seed extract protects against neuronal injury and improves cognitive function in rats with type II diabetes mellitus with cognitive impairmentpubmed:29138799
- (台灣農業研究67 (4): 355-364) 香菇柄水萃物改善糖尿病降低阿茲海默氏症罹病風險初探
- Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis PatientsPubmed: 30847765
- Cellular Metabolomics Reveal the Mechanism Underlying the Anti-Atherosclerotic Effects of Aspirin Eugenol Ester on Vascular Endothelial DysfunctionPubmed: 31261711
- Fushiming Capsule Attenuates Diabetic Rat Retina Damage via Antioxidation and Anti-Inflammation
- Effect of Advanced Glycation End Products on the Progression of Alzheimer's DiseasePubmed: 31561370
- Protective effect of vanillin on diabetic nephropathy by decreasing advanced glycation end products in ratsPubmed: 31759039
- Supplementation with Korean Red Ginseng Improves Current Perception Threshold in Korean Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo …Pubmed: 32025522
- A New Insight into Meloxicam: Assessment of Antioxidant and Anti-Glycating Activity in In Vitro StudiesPubmed: 32927809
- Advanced glycation end products enhance macrophage polarization to the M1 phenotype via the HIF-1α/PDK4 pathwayPubmed: 32464167
- The effect of Korean Red Ginseng on sarcopenia biomarkers in type 2 diabetes patientsPubmed: 32470863
- The Role of PPARγ in Hyperglycemia-induced Deleterious Effect on Chondrocytes
- Young and Undamaged rMSA Improves the Healthspan and Lifespan of Mice34439857
- Dietary Advanced Glycation End Products Shift the Gut Microbiota Composition and Induce Insulin Resistance in MicePubmed:35210793